Form 8-K - Current report:
SEC Accession No. 0001437749-24-035521
Filing Date
2024-11-15
Accepted
2024-11-15 17:24:18
Documents
19
Period of Report
2024-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K nrxp20241115_8k.htm   iXBRL 8-K 33573
2 EXHIBIT 99.1 ex_748946.htm EX-99.1 46803
7 graph01.jpg GRAPHIC 39303
8 graph02.jpg GRAPHIC 18888
9 graph03.jpg GRAPHIC 34667
10 nrx01.jpg GRAPHIC 2352
  Complete submission text file 0001437749-24-035521.txt   374222

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nrxp-20241114.xsd EX-101.SCH 3912
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrxp-20241114_def.xml EX-101.DEF 13474
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrxp-20241114_lab.xml EX-101.LAB 17731
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrxp-20241114_pre.xml EX-101.PRE 13451
21 EXTRACTED XBRL INSTANCE DOCUMENT nrxp20241115_8k_htm.xml XML 4870
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

EIN.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 241468988
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)